Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Shares Outstanding (Weighted Average) (2019 - 2025)

Bioadaptives' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $8.2 million for Q4 2024.

  • For Q4 2024, Shares Outstanding (Weighted Average) rose 37.57% year-over-year to $8.2 million; the TTM value through Dec 2024 reached $8.2 million, up 37.57%, while the annual FY2024 figure was $8.2 million, 37.57% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2024 was $8.2 million at Bioadaptives, down from $1.1 billion in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $1.1 billion in Q3 2024 and bottomed at $6.0 million in Q4 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $43.7 million (2021), against an average of $249.9 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 717.17% in 2023 against a maximum downside of 94.37% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $20.4 million in 2020, then surged by 65.51% to $33.7 million in 2021, then soared by 214.17% to $106.0 million in 2022, then crashed by 94.37% to $6.0 million in 2023, then soared by 37.57% to $8.2 million in 2024.
  • Per Business Quant, the three most recent readings for BDPT's Shares Outstanding (Weighted Average) are $8.2 million (Q4 2024), $1.1 billion (Q3 2024), and $895.8 million (Q2 2024).